253 results about "Pulmonary acariasis" patented technology

A computer implemented method for quantifying and predicting the progression of interstitial lung disease is disclosed herein. The method comprises obtaining at least one image based on a scan of at least a part of a patient's lung, segmenting the image to obtain a lung mask defining the periphery of the lung and to identify structures within the lung mask, and applying a weighting to the identified structures based on the relative position of the structures relative to the lung periphery to obtain a weighted score. The method may then comprise quantifying the extent of interstitial lung disease, and / or predicting the progression of interstitial lung disease, based on the weighted score.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The present invention provides compounds of formula I for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonosis, nonalcoholic steatohepatitis (NASH), interstitial lung disease (ILD), and idiopathic pulmonary fibrosis (IPF). JPEG2026504613000125.jpg8493 (in the formula, R 1 , R 2 , R 3 , R 4 , A, D, E, G, J, K, and L are as defined in claim 1), and prodrugs, deuterated analogs, and pharmaceutically acceptable salts thereof.

An early screening system for chronic obstructive pulmonary disease based on blood routine test data. It belongs to the technical field of digital medical treatment, and specifically relates to the technical field of intelligent early screening of chronic obstructive pulmonary disease. It solves the technical problem that the generalization ability of a COPD prediction model is limited due to differences between different research data sets. The system comprises a data collection module that collects blood routine test data of a plurality of chronic obstructive pulmonary disease patients and blood routine test data of a plurality of normal personnel; a data preprocessing module that performs standardization processing on the blood routine test data to obtain a standardized data set; a screening model training module that trains N classification models using the standardized data set and calculates the prediction accuracy of each classification model; and a screening model application module that obtains the fusion weight of each model by using a normalization processing method based on the prediction accuracy of each classification model, fuses the risk scores predicted by the multiple models, and obtains a final screening result.

A medicament for treatment or prevention of interstitial lung disease, and of a disease or symptom accompanied by systemic sclerosis in a subject, the medicament comprising, as an effective ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or co-crystal thereof.

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

The present invention provides new devices, systems, and methods for delivering enriched oxygen to recipients (e.g., chronically ill patients, such as COPD patients). One aspect is a more efficient portable oxygen concentrator that is configured to deliver an enriched oxygen airflow having a significantly lower overall oxygen concentration and greater overall volume administered as compared to currently marketed or known portable oxygen concentrators. Administering the lower oxygen concentration at higher volumes allows for the present portable oxygen concentrators to deliver an equivalent number of moles of oxygen as administered by traditional portable concentrators while increasing the efficiency of the system and the ability of the system to maintain the therapeutic level of oxygen concentration for a longer period.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The invention belongs to the field of respiratory system disease treatment, and provides application of a gymnadenia conopsea extract in preparation of a medicine for treating or preventing pulmonary edema. The embodiment of the invention proves that both the gymnadenia conopsea alcohol extract and the gymnadenia conopsea water extract can effectively improve indexes such as pulmonary edema respiratory rate, minute ventilation volume, rising tidal volume, inspiration peak flow, expiration peak flow and the like, and improve arterial blood-gas indexes and inflammatory factor level in alveolar lavage fluid. The invention provides the application of the gymnadenia conopsea alcohol extract and the gymnadenia conopsea water extract in the medicine for treating or preventing lung diseases, especially pulmonary edema for the first time, the traditional medicine gymnadenia conopsea is fully developed and utilized, and a safe and effective means is provided for treating the critical disease pulmonary edema.

This disclosure relates to a method, system, and dynamic X-ray camera for intelligent identification of chronic obstructive pulmonary disease (COPD), belonging to the field of intelligent COPD identification technology. The intelligent COPD identification method includes: acquiring one or more of the following dynamic X-ray quantitative parameters from a sequence of left lung field area parameters, right lung field area parameters, left diaphragm parameters, right diaphragm parameters, and cardiothoracic ratio parameters corresponding to multiple dynamic two-dimensional chest X-ray images during respiration; and performing intelligent COPD identification based on one or more of the dynamic X-ray quantitative parameters from the left lung field area parameters, right lung field area parameters, left diaphragm parameters, right diaphragm parameters, and cardiothoracic ratio parameters, using a preset intelligent COPD identification model. The embodiments of this disclosure can achieve intelligent identification of chronic obstructive pulmonary disease.

Novel kisspeptin-13 or KP-13 peptides and KP-13 satellites or modified peptides (KPSATs) are disclosed having improved therapeutic benefits in regulating pathophysiological changes in various tissues, particularly lung tissue. These KPSATs have improved antiproliferative effects and non-cytotoxic effects on airway smooth muscle cells and tissue.

A system configured for use in diagnosing a respiratory health condition of a patient comprising: processor configured to: provide image data of lungs of a patient; derive two or more features from the image data; combine the two or more features to produce a composite feature; use the composite feature to diagnose the presence of a respiratory health condition in the lungs of the patient.

The present invention provides methods and compositions for the treatment of chronic lung disease (CLD), comprising administering to a subject in need of treatment a composition comprising insulin-like growth factor-1 (IGF-1).

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

The invention provides a lung rare disease CT image automatic auxiliary diagnosis system based on deep learning, and belongs to the technical field of deep learning and auxiliary diagnosis, and the system comprises a data collection and preprocessing module which is used for carrying out the privacy processing, format conversion, standardization processing and data enhancement of CT image data, and outputting a three-dimensional input block meeting the model input requirements; the three-dimensional feature modeling and training module is used for taking the three-dimensional compact connection neural network as a core, learning morphological and distribution features of cystic lesions through a training strategy, and constructing and training to obtain a disease classification model; the online reasoning and interpretable display module is used for performing probability calibration on the trained model output to generate a visual result; and the clinical application module is used for receiving the current preprocessed CT image, inputting the CT image into the calibrated model for processing and analysis, and outputting a classification result and a visualization basis. High-dimensional structure modeling and credible reasoning of the rare diffuse lung disease image are realized, and AI auxiliary diagnosis is facilitated.

This invention discloses a Tibetan medicine formula called Mabosongtang Lung-Nourishing Composition and its preparation method and application in modern formulations, more specifically relating to a preparation method and application of Mabosongtang Lung-Nourishing granules, oral liquid, and capsules. The composition is mainly prepared from the following medicinal materials: Tibetan Lithospermum erythrorhizon, Tibetan Rubia cordifolia, Lithospermum erythrorhizon, Bambusa textilis, Morinda officinalis, Lysimachia christinae, Hippophae rhamnoides, and Glycyrrhiza uralensis. The aqueous extract of this composition, with appropriate excipients, is prepared into granules, oral liquid, and capsules using modern pharmaceutical processes. The three formulations are effective, rationally formulated, advanced in dosage form, and stable in quality. They have the effects of calming the lungs, suppressing blood stasis, and clearing lung heat. They can be used for respiratory symptoms caused by the invasion of pathogenic factors into the lungs, and dysfunction of the lung's vital energy and ascending qi, such as cough, wheezing, shortness of breath, etc. (treatment of lung diseases with the above symptoms).

Provided is a pharmaceutical for lung regeneration, the pharmaceutical containing vascular endothelial stem cells. Also provided is a method for producing an alveolar organoid, the method comprising a step for three-dimensional co-culture of vascular endothelial stem cells and alveolar epithelial cells. This pharmaceutical for lung regeneration is useful in the treatment of lung disease accompanied by alveolar damage, such as chronic obstructive lung diseases, infectious lung diseases, and pulmonary fibrosis.

The application provides a recovery training device for chronic obstructive pulmonary disease, and belongs to the technical field of recovery training for chronic obstructive pulmonary disease. The recovery training device for chronic obstructive pulmonary disease comprises a base, a training mechanism is arranged on the top of the base, the training mechanism comprises an installation plate and a first training ball, the installation plate is fixedly arranged on the top of the base, the installation plate is provided with two, the top of each of the two installation plates is fixedly provided with a first training cylinder and a second training cylinder. The training mechanism is arranged, when performing exhalation training, the user blows, the gas in the blowing pipe lifts the first training ball upward, and when the first training ball reaches the top of the first training cylinder, the user stops blowing, and the first training ball falls due to gravity; when performing inhalation training, the user inhales, a negative pressure is generated in the second training cylinder at this time, the second training ball moves upward, so that the user can conveniently perform inhalation and blowing training.

The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the treatment of rare chronic inflammatory pulmonary diseases. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

The application discloses a kind of non-tuberculous mycobacterial lung disease and pulmonary tuberculosis CT image classification method, mainly including the following steps: image feature map is extracted by encoder and image feature map is divided into multiple examples, each example represents the feature information in certain area of image;The correlation weight of example and classification task is calculated, and the example is aggregated into bag feature representation according to the weight to express the characteristics of CT image;Bag feature representation is predicted as CT image category by classifier;According to the correlation weight, important examples are selected, and are evaluated by classifier, to express the correlation degree of the learning content and expected content of network;Loss function is constructed, including bag classification loss and correlation loss, respectively representing the difference between CT predicted value and true value and the difference between model learning content and expected content.The method can realize the binary classification of non-tuberculous mycobacterial lung disease and pulmonary tuberculosis CT image, and is superior to the classification accuracy of existing method.

The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,whereinwherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compoundsfor the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating interstitial lung disease with fibrosis and a preparation method and application thereof.The traditional Chinese medicine composition is prepared from, by weight, 5-15 parts of ginseng, 8-15 parts of radix asparagi, 10-20 parts of radix rehmanniae recen, 15-25 parts of astragalus membranaceus, 5-15 parts of schisandra chinensis, 15-25 parts of honey-fried radix asteris, 15-25 parts of honey-fried flos farfarae, 8-15 parts of curcuma zedoary, 8-15 parts of peach kernels and 8-15 parts of herba epimedii. , 15-30 parts of semen lepidii, 10-20 parts of fructus liquidambaris, and 10-20 parts of semen sinapis. The traditional Chinese medicine composition provided by the invention has the effects of strengthening vitality, reducing phlegm, activating blood, removing blood stasis and dredging collaterals, and can improve clinical symptoms of patients with interstitial lung diseases and fibrosis, improve life quality and delay disease progression.

FIELD: molecular biology.SUBSTANCE: method for predicting a high risk of adverse outcome in a patient with purulent lung disease (PLD) infected with gram-negative bacteria of the Klebsiella pneumoniae species is described. The method involves isolating DNA from peripheral venous blood and determining variants of the AQP4 rs1058424 gene. When the AQP4 rs1058424 AA genotype is detected in a patient with PLD and the presence of signs of Klebsiella pneumoniae infection, a high risk of death is determined.EFFECT: based on the determination of the AQP4 rs1058424 genotype for patients with PLD and identified gram-negative bacteria, it becomes possible to fairly early divide hospitalized patients with purulent infection into high-risk and low-risk groups for a fatal outcome.1 cl, 4 ex

The present disclosure, relates, in general, to methods of treating chronic obstructive pulmonary disease (COPD) using an antibody specific for thymic stromal lymphopoietin (TSLP).

The invention relates to a medicament containing gold for use in the prevention or therapy of chronic obstructive pulmonary disease (COPD), preferably with accompanying respiratory tract infection, wherein the medicament is administered by inhalation. The invention further relates to a process for preparing a ready-to-administer solution of a medicament containing gold.

A method for treating or preventing chronic obstructive pulmonary disease (COPD) in a subject is provided. The method includes administering a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or an antigen-binding fragment thereof, to a subject in need.

The invention discloses a construction method of an endothelial cell knockout Cdc42 gene aggravated bleomycin induced pulmonary fibrosis mouse model, which comprises the following steps of: mating a Cdc42 gene conditional knockout mouse with a mouse (Tie2-CreER) of which the endothelial cell specifically expresses tamoxifen induced Cre recombinase to obtain a double-transgenic mouse (Cdc42fl / fl-Tie2-CreER); the Cdc42 gene is specifically knocked out in vascular endothelial cells under the induction of tamoxifen, and then pulmonary fibrosis is induced by subcutaneous injection of bleomycin. The model shows aggravated pulmonary fibrosis phenotypes, including collagen deposition increase, alveolar structure damage and fibrosis-related protein expression up-regulation, and is high in construction success rate and good in repeatability. The invention also provides an application of the model in research of systemic sclerosis related interstitial lung disease pathogenesis and screening of anti-pulmonary fibrosis drugs, and an application of the Cdc42 gene as a drug target, and provides an accurate and reliable tool for pulmonary fibrosis research.

Compositions and methods for treating chronic obstructive pulmonary disease, interstitial lung disease, asthma, bronchitis, pneumonia, cystic fibrosis, pulmonary edema, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, acute respiratory distress syndrome, and respiratory syncytial virus in a patient are presented. Embodiments of the composition include a combination of diethylcarbamazine (DEC) and a prostacyclin analogue, such as Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost. Other embodiments include fluvoxamine and / or a phosphodiesterase (PDE) inhibitor. Some embodiments of the composition are in the form of an aerosol, include a propellent, or are in an inhalation delivery device.

The present invention relates to compositions, methods and kits for treating or preventing the effects of smoke exposure. In particular, these compositions, methods and kits are particularly suitable for, but not limited to, treatment or prevention of acute or chronic smoke exposure. In one aspect, the invention provides a method of treating or preventing obstructive pulmonary disease associated with or caused by smoke exposure in a subject in need thereof, the method comprising administering to the subject an antisense oligonucleotide (AON) that promotes the production of endogenous soluble RAGE, thereby treating or preventing obstructive pulmonary disease associated with or caused by exposure to smoke in the subject.